For healthcare professionals only.
EU Summary of Product Characteristics for REVLIMIDReady to learn more about proven survival in newly diagnosed TNE MM?
MM=multiple myeloma; TNE=transplant non-eligible.
triplet for
NDMM*
03/19 INT-REV190006
Indication
REVLIMID as combination therapy with dexamethasone, or bortezomib
and dexamethasone, or melphalan and prednisone (see section 4.2)
is indicated for the treatment of adult patients with previously untreated
multiple myeloma who are not eligible for transplant.
*REVLIMID+bortezomib+dexamethasone.
NDMM=newly diagnosed multiple myeloma.